Habit
Frequent edible use can affect cognition, mood regulation, and daytime performance.[1315,1499,1544, etc.]
Superscript reference numbers link to the Sources bibliography.
Composite Rating
Blends evidence depth, community direction, safety friction, and completeness.
Evidence Intensity
100/100
High depth from human/RCT/meta counts
Community Direction
0
Mixed / Neutral • confidence Minimal
Safety Friction
85/100
High signal from adverse/interaction markers
Data Completeness
100%
Studies 24 • mentions 0 • links 35
Not medical advice. This product is for educational and informational purposes only. It does not diagnose, treat, cure, or prevent any disease and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition.
FDA disclaimer: These statements have not been evaluated by the Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. Results may vary. Not intended for use by pregnant or nursing women, individuals under 18, or those with known medical conditions without physician consultation.
If you are experiencing a medical emergency, call 911 or your local emergency number immediately.
Classification: reduce.[1064,1176,1315, etc.]
Best fit: Users with nightly use and next-day cognitive fog reports..[1064,1176,1315, etc.]
Goal alignment: Brain Health, Mood, Sleep, Metabolic Health.[1064,1176,1315, etc.]
Classification
Reduce
Evidence Tier
HIGH
Best Fit
Users with nightly use and next-day cognitive fog reports.
Primary Focus
Brain Health, Mood
Clinical Depth
Humans: 117 • RCTs: 18 • Meta: 3
Cohort / Real-World
Cohort signals: 6
Safety Markers
Adverse signals: 11 • Interactions: 0
Freshness, trend, and study timeline for this item
Status
Trend
→ Stable evidence base
Depth
117 total studies · 6 recent
Timeline
Total indexed
117
Human studies
117
In vitro / tissue
36
Neuropsych signals
21
Randomized trials
18
Safety adverse signals
11
Weighted direction score: 0 (Mixed / Neutral)
High when replicated human meta-analysis/trial/cohort depth is present for the habit or exposure.
Total indexed
117
Human studies
117
In vitro / tissue
36
Neuropsych signals
21
Randomized trials
18
Safety adverse signals
11
Dependency signals
10
Cardiometabolic signals
9
Cohort signals
6
Sleep signals
5
Meta-analyses
3
Distribution of evidence by study design strength
Evidence Strength: High
PMID 32197092 • 2020 Apr
Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.
The lancet. Psychiatry
Open PubMedPMID 1338216 • 1992 Sep-Oct
Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH).
Journal of analytical toxicology
Open PubMedPMID 38850302 • 2024 Nov
Quantitative summary on the human pharmacokinetic properties of cannabidiol to accelerate scientific clinical application of cannabis.
Benefit reports: 0
Adverse reports: 0
No-effect reports: 0
Mixed reports: 0
Unclear reports: 0
Signal confidence: 0.00
Benefits
Adverse
No Effect
Community confidence 0.00 with mentions: benefit 0, adverse 0, no-effect 0.
Search fetch failed: Failed to fetch after retries: https://old.reddit.com/search.json?raw_json=1&sort=relevance&t=year&limit=8&q=%22cannabis%20edibles%22%20(exercise%20OR%20training%20OR%20sleep%20OR%20habit%20OR%20side%20effects%20OR%20experience%20OR%20results)%20(subreddit%3AFitness%20OR%20subreddit%3Abodyweightfitness%20OR%20subreddit%3Aweightroom%20OR%20subreddit%3Arunning%20OR%20subreddit%3ACycling%20OR%20subreddit%3Aswimming%20OR%20subreddit%3AHIIT%20OR%20subreddit%3Ayoga%20OR%20subreddit%3Abiohackers%20OR%20subreddit%3Alongevity%20OR%20subreddit%3Ameditation%20OR%20subreddit%3Asleep%20OR%20subreddit%3Astopsmoking%20OR%20subreddit%3Astopdrinking%20OR%20subreddit%3Aleaves%20OR%20subreddit%3Adecaf%20OR%20subreddit%3Adecidingtobebetter)
aggregate • unclear
No directional first-hand mentions captured in the current community corpus; source links are retained for traceability.
Open mentionEvidence Sources
PUBMED • Human lifestyle/habit literature
Counts from structured habit/exposure PubMed query set.
Outcome: Humans 116, RCT 18, meta 3, cohort 6, sleep signals 5, cardiometabolic signals 9.[1315,1499,1544, etc.]
Open sourcePUBMED • 2020 • Human evidence curation set
PMID 32197092 from The lancet. Psychiatry.
Outcome: See linked PubMed abstract for methods and outcomes.[, etc.]
No directional mention volume was resolved; fallback profile metadata is shown in other sections.
Animal-only studies
0
Composite of study volume, RCTs, and meta-analyses
Naunyn-Schmiedeberg's archives of pharmacology
PMID 40248111 • 2025
Double-Blind, Randomized, Placebo-Controlled, Crossover Study of Oral Cannabidiol and Tetrahydrocannabinol for Essential Tremor.
Tremor and other hyperkinetic movements (New York, N.Y.)
Open PubMedPMID 23146820 • 2013 Jun 1
Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?
Drug and alcohol dependence
Open PubMedPMID 38900958 • 2025 Mar 14
Randomized Laboratory Study of Single-Dose Cannabis, Dronabinol, and Placebo in Patients With Schizophrenia and Cannabis Use Disorder.
Schizophrenia bulletin
Open PubMedPMID 40288059 • 2025 Jul 1
A within-subject cross-over trial comparing the acute effects of oral delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in healthy adults.
Drug and alcohol dependence
Open PubMedPMID 17481836 • 2008 Jan 30
Excretion of Delta9-tetrahydrocannabinol in sweat.
Forensic science international
Open PubMedPMID 38832949 • 2024 Oct
Sex differences in the acute effects of oral THC: a randomized, placebo-controlled, crossover human laboratory study.
Psychopharmacology
Open PubMedPMID 19349314 • 2009 Apr
Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis.
Archives of general psychiatry
Open PubMedPMID 37088409 • 2023 May
Cannabinoid modulation of corticolimbic activation during extinction learning and fear renewal in adults with posttraumatic stress disorder.
Neurobiology of learning and memory
Open PubMedPMID 27806250 • 2016 Jul-Sep
Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
Open PubMedPMID 28407543 • 2017 Jun 1
Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration.
Drug and alcohol dependence
Open PubMedPMID 25532865 • 2015 Jan
Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Open PubMedPMID 38498958 • 2024 Apr 1
Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis.
Drug and alcohol dependence
Open PubMedPMID 24055595 • 2014 Sep
Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans.
Neurobiology of learning and memory
Open PubMedPMID 22796109 • 2013 Jan
Cannabinoid facilitation of fear extinction memory recall in humans.
Neuropharmacology
Open PubMedPMID 19924114 • 2010 Feb
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Open PubMedPMID 21362108 • 2011 Sep
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.
European journal of neurology
Open PubMedPMID 22878432 • 2013 Jan
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
Journal of neurology
Open PubMedPMID 6149589 • 1984
Reinforcing properties of oral delta 9-tetrahydrocannabinol, smoked marijuana, and nabilone: influence of previous marijuana use.
Psychopharmacology
Open PubMedPMID 32243711 • 2020 Apr
Potential oral health effects of e-cigarettes and vaping: A review and case reports.
Journal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.]
Open PubMedPMID 18847571 • 2008 Aug
[Delta-9-tetrahydrocannabinol pharmacokinetics].
Annales pharmaceutiques francaises
Open PubMedPMID 27883985 • 2016 Dec
A systematic review of passive exposure to cannabis.
Forensic science international
Open PubMedFallback search fetch failed: Failed to fetch after retries: https://old.reddit.com/search.json?raw_json=1&sort=relevance&t=year&limit=12&q=cannabis%20edibles
Community Sources
PUBMED • 1992 • Human evidence curation set
PMID 1338216 from Journal of analytical toxicology.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2024 • Human evidence curation set
PMID 38850302 from Naunyn-Schmiedeberg's archives of pharmacology.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2025 • Human evidence curation set
PMID 40248111 from Tremor and other hyperkinetic movements (New York, N.Y.).
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2013 • Human evidence curation set
PMID 23146820 from Drug and alcohol dependence.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2025 • Human evidence curation set
PMID 38900958 from Schizophrenia bulletin.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2025 • Human evidence curation set
PMID 40288059 from Drug and alcohol dependence.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2008 • Human evidence curation set
PMID 17481836 from Forensic science international.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2024 • Human evidence curation set
PMID 38832949 from Psychopharmacology.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2009 • Human evidence curation set
PMID 19349314 from Archives of general psychiatry.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2023 • Human evidence curation set
PMID 37088409 from Neurobiology of learning and memory.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2016 • Human evidence curation set
PMID 27806250 from Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2017 • Human evidence curation set
PMID 28407543 from Drug and alcohol dependence.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2015 • Human evidence curation set
PMID 25532865 from European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2024 • Human evidence curation set
PMID 38498958 from Drug and alcohol dependence.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2014 • Human evidence curation set
PMID 24055595 from Neurobiology of learning and memory.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2013 • Human evidence curation set
PMID 22796109 from Neuropharmacology.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2010 • Human evidence curation set
PMID 19924114 from Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2011 • Human evidence curation set
PMID 21362108 from European journal of neurology.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2013 • Human evidence curation set
PMID 22878432 from Journal of neurology.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 1984 • Human evidence curation set
PMID 6149589 from Psychopharmacology.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2020 • Human evidence curation set
PMID 32243711 from Journal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.].
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2008 • Human evidence curation set
PMID 18847571 from Annales pharmaceutiques francaises.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open sourcePUBMED • 2016 • Human evidence curation set
PMID 27883985 from Forensic science international.
Outcome: See linked PubMed abstract for methods and outcomes.[1315,1499,1544, etc.]
Open source